|Dr. John D. Dobak||Pres, CEO & Director||667.76k||N/A||1966|
|Mr. Kevin Sun M.B.A.||CFO, Treasurer & Sec.||378.15k||N/A||1978|
|Ms. Claudia Ibarra||Chief Operating Officer||350.39k||N/A||1962|
|Mr. Michael Howell Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Ray Akhavan J.D.||Gen. Counsel||N/A||N/A||N/A|
|Mr. Ray Bassi||VP of Sales||N/A||N/A||N/A|
|Dr. Burkhard Jansen||Chief Medical Affairs Officer||N/A||N/A||1966|
|Dr. Zuxu Yao Ph.D.||Head of Advanced Innovation||N/A||N/A||1963|
|Mr. Todd Michael Wood||Chief Commercial Officer||N/A||N/A||1969|
|Mr. Daniel Visage||Sr. VP of Payer Access||N/A||N/A||N/A|
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
DermTech, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 9.